REPORT SCOPE
INTRODUCTION
This report updates BCC's report Market for Bioengineered Protein Drugs and reviews the global markets for the different types of protein drugs as well as forecasts for trends and sales through 2011. Important research developments, regulatory trends and other factors influencing demand will be discussed.
Protein drugs, as the name suggests, are pharmaceuticals based on proteins or portions of proteins. Also referred to as biologics, protein drugs have become increasingly important over the past 5 years with the advent of high throughput screening and proteomics combined with the changing (some would say declining) health status of the developed countries, particularly the United States.
Technologies included in this report are: protein therapeutics, proteomics, bioengineered protein drugs, recombinant protein drugs, protein arrays, protein expression and protein purification, and protein chips.
Drugs included in this report are insulin, coagulants, interferons, cytokines, bioengineered antibodies, enzymes, hormones (particularly growth hormones), growth factors, interleukins and angiogenesis inhibitors.
Diseases for which protein drugs are particularly amenable and that will be discussed in this report include: hemophilia, diabetes, cancer, cystic fibrosis, hepatitis, psoriasis and congenital diseases.
SCOPE OF STUDY
This report contains:
- Coverage of proteins that are used for therapeutic purposes, including an analysis of protein-based drugs in clinical trials
- Market trends and five-year forecasts with projections through 2011
- Examination of current technologies underlying the market and details the effects of new technologies on this market
- Profiles of the major companies involved in the production and modification of protein drugs.
- An analysis of the patent landscape in this field and the companies with the greatest breadth in their IP portfolios.
METHODOLOGY AND SOURCES
This report uses a combination of direct and indirect sources. Direct sources include interviews and conversations with scientists, analysts and research consultants. Indirect sources include company news releases, governmental and nongovernmental agencies, scientific journals and the popular press.
Sales were gathered from the most recently available data and represent worldwide sales. In nearly all cases, this involved year-end 2005 sales. If these figures were not available, then the latest available figures were used.
In some cases, data was not available. In these cases estimates were made based on indirect data, such as patient populations, percentages treated with other drugs and average sales prices.
Estimates for future sales growth within individual markets depended upon: patent expirations, percentage of the market penetrated, generic competition, competing drug classes, the introduction of new drugs, demographic growth and shifts, recent study results, and other variables. In each case where a forecast is made, the most important factors are listed.
Sales are presented in millions of dollars, unless otherwise noted.
ANALYST CREDENTIALS
Gargi Talukder has a doctorate in Neuroscience from Stanford University and a law degree from the University of Chicago. She has over 10 years of experience in the biotechnology sector.
